CoChat
Sign Up
Cited by 34Cardiac electrophysiology and arrhythmiasCardiac Arrhythmias and TreatmentsIon channel regulation and function

Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations

Open access
Szél, Tamás, Koncz, István, Jost, Norbert, Baczkó, István, Husti, Zoltán, Virág, László, Bussek, Alexandra, Wettwer, Erich +3 more·2011·European Journal of Pharmacology
DOI 10.1016/j.ejphar.2011.04.042
Open this paper in CoChat — free account

Abstract

The aim of this study was to investigate the cellular electrophysiological effects of ranolazine on action potential characteristics. The experiments were carried out in dog and human cardiac preparations using the conventional microelectrode technique. In dog Purkinje fibres ranolazine produced a concentration- and frequency-dependent depression of the maximum rate of depolarization (V(max)) while action potential duration (APD) was shortened. In dog and human right ventricular papillary muscle ranolazine exerted no significant effect on APD, while it produced, like mexiletine, use-dependent depression of V(max) with relatively fast onset and offset kinetics. In dog midmyocardial preparations the drug did not exert statistically significant effect on repolarization at 10 μM, although a tendency toward prolongation was observed at 20 μM. A moderate lengthening of APD(90) by ranolazine was noticed in canine atrial preparations obtained from dogs in sinus rhythm and in tachypacing induced remodelled preparations. Use-dependent depression of V(max) was more pronounced in atria from dogs in sinus rhythm than those in remodelled atria or in the ventricle. These findings indicate that ranolazine, in addition to its known late sodium current blocking effect, also depresses peak I(Na) with class I/B antiarrhythmic characteristics. Although peak I(Na) inhibition by ranolazine is stronger in the atria, it is also substantial (at fast stimulation frequencies) in ventricular preparations. Ranolazine also decreased the dispersion of ventricular repolarization (the difference in APD(90) values between Purkinje fibres and papillary muscles), which can contribute to the antiarrhythmic property of the drug.

Integrity signals

Registry

Crossref · 10.1016/j.ejphar.2011.04.042

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Canine action potential duration is only slightly shorter than human action potential duration and is more comparable than previously discussed animal models (canine APD90 ~219 ms vs human ~290 ms in right ventricular papillary muscles at 1000 ms cycle length and 37 degrees C).

    “The action potential duration of canine is only a little bit shorter than that of humans, much more comparable than the animal models discussed previously (canine APD90: ~ 219 ms, human APD90: ~290 ms both measured in right ventricular papillary muscles at cycle length of 1000 ms and 37 °C) (Szel et al. 2011).”

    From Small and large animal models in cardiac contraction research: advantages and disadvantages (2014) · cites this paper as Szel et al. 2011

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Szél, T., Koncz, I., Jost, N., Baczkó, I., Husti, Z., Virág, L., Bussek, A., Wettwer, E., Ravens, U., Papp, J. G., & Varró, A.
Affiliations
  • University of Szeged (HU)
  • Hungarian Academy of Sciences (HU)
  • Technische Universität Dresden (DE)
Corresponding author
Varró, András
ORCID
Venue
European Journal of Pharmacology
Publisher
Elsevier BV
Published
2011-07
Volume
662
Issue
1-3
Pages
31-39
ISSN
0014-2999 (ISSN-L)
DOI
10.1016/j.ejphar.2011.04.042
OpenAlex
W2001197934
Cited by
34
References
38
Citations by year
2023: 2 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 4 · 2014: 1 · 2013: 4 · 2012: 4
FWCI
2.63
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Funders
  • Hungarian Scientific Research Fund (OTKA CNK-77855, OTKA K-82079)
  • Hungarian Ministry of Health (ETT 302-03/2009, ETT 306-03/2009)
  • Hungarian National Office for Research and Technology — Hungarian National Technology Programme (TECH_08_A1_CARDIO08)
  • National Development Agency (TÁMOP-4.2.2-08/1-2008-0013)
  • European Community (ICT-2008-224381)
  • Hungarian Academy of Sciences
  • János Bolyai Research Scholarship
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
Keywords
ranolazine, sodium channel blockade, action potential duration, Purkinje fibers, papillary muscle, atrial remodeling, tachypacing, dispersion of repolarization, mexiletine, antianginal drugs, cardiac electrophysiology
MeSH terms
Ranolazine, Acetanilides, Angina Pectoris, Animals, Anti-Arrhythmia Agents, Dogs, Female, Heart, Heart Atria, Humans, Kinetics, Male, Membrane Potentials, Papillary Muscles, Piperazines, Purkinje Fibers, Atrial Function, Electrophysiological Phenomena, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review